A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Ribociclib (Primary)
- Indications Liposarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 22 Nov 2016 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2016 Status changed from not yet recruiting to recruiting.